74 results
8-K/A
EX-99.2
KPRX
Kiora Pharmaceuticals Inc
5 Mar 21
Financial Statements and Exhibits
4:15pm
of which from social security
of which with a residual term of up to one year
1.110.915,89
1.111
1.203
of which with a residual term of up to one year … ) Social security expenses
Depreciation and amortization
a) on intangible and tangible fixed assets
other operating expenses
Subtotal of items 1
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
17 Dec 19
EyeGate Pharma Receives $1.9 Million From Exercised Warrants
8:41am
delivery system, the EyeGate II Delivery System.
For more information, please visit www.EyeGatePharma.com.
EyeGate Social Media
EyeGate uses its website … . Therefore, investors should monitor EyeGate’s website and its social media accounts in addition to following its press releases, SEC filings, public
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
25 Sep 18
EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules
6:58am
visit www.EyeGatePharma.com.
EyeGate Social Media
EyeGate uses its website (www.EyeGatePharma.com), Facebook page (https://www.facebook.com … these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor EyeGate’s website and its social media
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
14 May 19
EyeGate Pharma Receives Positive Nasdaq Listing Determination
6:55am
Delivery System. For more information, please visit www.EyeGatePharma.com.
EyeGate Social Media
EyeGate uses its website (www.EyeGatePharma.com), Facebook … EyeGate’s website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
23 Sep 19
Other Events
6:57am
Social Media
EyeGate uses its website (www.EyeGatePharma.com), Facebook page (https://www.facebook.com/ EyeGatePharma/), corporate Twitter account … obligations under Regulation FD. Therefore, investors should monitor EyeGate’s website and its social media accounts in addition to following its press
8-K
EX-99.1
z67hclsmt1n93
29 Aug 19
Material Modifications to Rights of Security Holders
12:45pm
8-K
EX-99.1
et9 tkzu85bx6
30 Sep 19
EyeGate Enters Into Agreement for $1.9 Million Private Placement
6:55am
8-K
EX-99.1
52xlsv
16 May 18
EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd
4:40pm
8-K
EX-99.1
jpa5ff
13 Nov 18
Eyegate Pharma Announces Positive Results In Second PRK Study
7:00am
8-K
EX-99.1
ew0zmz 29ucl0
2 Oct 18
EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care
6:58am
8-K
EX-99.1
b8ftz8ckfijfb8xdw32g
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-99.2
hjbjtemh5fxf
13 Nov 18
Eyegate Pharma Announces Positive Results In Second PRK Study
7:00am
8-K
EX-99.1
ll05qp2
2 Dec 19
EyeGate Pharma Announces Additional Positive Top-Line Data in PRK Pivotal Study
6:55am
8-K
EX-99.1
nbz8q9lp4moz
22 Nov 19
Other Events
6:55am
8-K
EX-99.1
haxrwal8o
31 Mar 20
EyeGate Pharma Announces Positive Topline Data in Follow-on Dry Eye Pilot Study
6:55am
8-K/A
EX-99.1
v3tw5ypj7 rw8x
5 Mar 21
Financial Statements and Exhibits
4:15pm
8-K
EX-10.1
5epi9kwgkk
1 Feb 21
Departure of Directors or Certain Officers
6:55am
8-K
EX-99
o7k4m2
13 Oct 22
Other Events
6:45am
8-K
EX-99.1
pi1krsr1
21 Nov 22
Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million
7:00am
8-K
EX-99.1
k5fluzqevc
12 Dec 18
Regulation FD Disclosure
4:30pm